Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Severe hypertriglyceridemia associated with calaspargase pegol.

Severe hypertriglyceridemia associated with calaspargase pegol.

Journal: Leukemia & lymphoma
Published: August 09, 2025

Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol.

Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol.

Journal: Pediatric blood & cancer
Published: June 23, 2025

Asparagine Synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinoma.

Asparagine Synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinoma.

Journal: European journal of pharmacology
Published: March 12, 2025

Desensitization to calaspargase pegol appears to be less successful than pegaspargase.

Desensitization to calaspargase pegol appears to be less successful than pegaspargase.

Journal: Blood advances
Published: November 25, 2024

Desensitization to calaspargase pegol appears to be less successful than pegaspargase.

Desensitization to calaspargase pegol appears to be less successful than pegaspargase.

Journal: Blood advances
Published: November 25, 2024

Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature.

Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature.

Journal: Pediatric hematology and oncology
Published: August 28, 2024

Calaspargase pegol and pegaspargase cause similar hepatosteatosis in mice.

Calaspargase pegol and pegaspargase cause similar hepatosteatosis in mice.

Journal: Haematologica
Published: August 27, 2024

Attempted desensitization to calaspargase pegol: a familiar approach to a new problem.

Attempted desensitization to calaspargase pegol: a familiar approach to a new problem.

Journal: Leukemia & lymphoma
Published: November 22, 2023

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 06, 2021

Improving the Treatment of Acute Lymphoblastic Leukemia.

Improving the Treatment of Acute Lymphoblastic Leukemia.

Journal: Biochemistry
Published: August 14, 2020

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 29, 2014
Showing 1-11 of 11

Last Updated: 10/31/2025